Type C TP53-CDKN1A pathway dysfunction occurs independently of CDKN1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP53 abnormalities

Br J Haematol. 2017 Sep;178(5):824-826. doi: 10.1111/bjh.14172. Epub 2016 Jun 13.

Authors

Ian Tracy¹, William Tapper², Anton Parker¹, Anne Gardiner¹, Shalal Sadullah³, Guy Pratt⁴, Adrian Copplestone⁵, David Oscier¹, Oliver Giles Best¹

Affiliations

¹ Department of Molecular Pathology, Royal Bournemouth Hospital, Bournemouth, Dorset, UK.
² Genetic Epidemiology and Bioinformatics Research Group, Faculty of Medicine, University of Southampton, Southampton, UK.
³ Department of Haematology, James Paget University Hospitals, Great Yarmouth, UK.
⁴ Department of Haematology, Birmingham Heartlands Hospital, Birmingham, UK.
⁵ Department of Haematology, Derriford Hospital, Plymouth, UK.

PMID: 27292869
DOI: 10.1111/bjh.14172

No abstract available

Keywords: TP53; cell signalling; chronic lymphocytic leukaemia.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Alleles
Cyclin-Dependent Kinase Inhibitor p21 / genetics*
Cyclin-Dependent Kinase Inhibitor p21 / metabolism*
DNA Damage*
Gene Expression
Genotype
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
Leukemia, Lymphocytic, Chronic, B-Cell / metabolism*
Polymorphism, Genetic*
Polymorphism, Single Nucleotide
Signal Transduction*
Tumor Suppressor Protein p53 / genetics*
Tumor Suppressor Protein p53 / metabolism*

Substances

CDKN1A protein, human
Cyclin-Dependent Kinase Inhibitor p21
Tumor Suppressor Protein p53